## Matteo Tebaldi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3738981/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Shedding Light on Treatment Options for Coronary Vasomotor Disorders: A Systematic Review. Cardiovascular Drugs and Therapy, 2024, 38, 151-161.	1.3	2
2	The unbearable lightness of the instantaneous wave-free ratio/fractional flow reserve discordance. Journal of Cardiovascular Medicine, 2022, 23, 116-118.	0.6	1
3	Complete versus culpritâ€only strategy in older MI patients with multivessel disease. Catheterization and Cardiovascular Interventions, 2022, 99, 970-978.	0.7	4
4	Acetylcholine Use in Modern Cardiac Catheterization Laboratories: A Systematic Review. Journal of Clinical Medicine, 2022, 11, 1129.	1.0	6
5	Angiographyâ€derived versus invasivelyâ€determined index of microcirculatory resistance in the assessment of coronary microcirculation: A systematic review and metaâ€analysis. Catheterization and Cardiovascular Interventions, 2022, 99, 2018-2025.	0.7	11
6	Comparison of quantitative flow ratio, Pd/Pa and diastolic <scp>hyperemiaâ€free</scp> ratio versus fractional flow reserve in <scp>nonâ€culprit</scp> lesion of patients with non <scp>ST</scp> â€segment elevation myocardial infarction. Catheterization and Cardiovascular Interventions, 2021, 98, 1057-1065.	0.7	17
7	Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale. Journal of Cardiovascular Translational Research 2021, 14, 110-119	1.1	7
8	Usefulness of Coronary Sinus Reducer Implantation for the Treatment of Chronic Refractory Angina Pectoris. American Journal of Cardiology, 2021, 139, 22-27.	0.7	15
9	Safety, efficacy and impact on frailty of mini-invasive radial balloon aortic valvuloplasty. Heart, 2021, 107, 874-880.	1.2	13
10	Quantitative flow ratio as a new tool for angiography-based physiological evaluation of coronary artery disease: a review. Future Cardiology, 2021, 17, 1435-1452.	0.5	4
11	10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2021, 77, 1165-1178.	1.2	32
12	The impact of periprocedural myocardial infarction on mortality in older adults with non-ST-segment elevation acute coronary syndrome. Journal of Cardiovascular Medicine, 2021, Publish Ahead of Print, 546-552.	0.6	1
13	Coronary Microvascular Dysfunction: PET, CMR and CT Assessment. Journal of Clinical Medicine, 2021, 10, 1848.	1.0	24
14	Contrast Associated Acute Kidney Injury and Mortality in Older Adults with Acute Coronary Syndrome: A Pooled Analysis of the FRASER and HULK Studies. Journal of Clinical Medicine, 2021, 10, 2151.	1.0	8
15	Safety and efficacy of coronary sinus narrowing in chronic refractory angina: Insights from the RESOURCE study. International Journal of Cardiology, 2021, 337, 29-37.	0.8	12
16	The management of patients with acute myocardial infarction: route to tailored therapy. International Journal of Cardiology, 2021, 343, 1-2.	0.8	0
17	Cost-effectiveness of the coronary sinus Reducer and its impact on the healthcare burden of refractory angina patients. European Heart Journal Quality of Care & amp; Clinical Outcomes, 2020, 6, 32-40.	1.8	15
18	The Assessment of Scales of Frailty and Physical Performance Improves Prediction of Major Adverse Cardiac Events in Older Adults with Acute Coronary Syndrome. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 1113-1119.	1.7	49

#	Article	lF	CITATIONS
19	Adenosine-Free Indexes vs. Fractional Flow Reserve for Functional Assessment of Coronary Stenoses: Systematic Review and Meta-Analysis. International Journal of Cardiology, 2020, 299, 93-99.	0.8	7
20	Complete revascularization reduces cardiovascular death in patients with ST-segment elevation myocardial infarction and multivessel disease: systematic review and meta-analysis of randomized clinical trials. European Heart Journal, 2020, 41, 4103-4110.	1.0	59
21	Physiology-guided revascularization versus optimal medical therapy of nonculprit lesions in elderly patients with myocardial infarction: Rationale and design of the FIRE trial. American Heart Journal, 2020, 229, 100-109.	1.2	24
22	Angio-Based Index of Microcirculatory Resistance for the Assessment of the Coronary Resistance: A Proof of Concept Study. Journal of Interventional Cardiology, 2020, 2020, 1-4.	0.5	36
23	Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment–Elevation Myocardial Infarction. Circulation, 2020, 142, 441-454.	1.6	67
24	Index of microcirculatory resistance assessment in patients with new diagnosis of left ventricular dilatation without significant coronary artery lesions: IMPAIRED pilot trial. European Journal of Heart Failure, 2020, 22, 561-563.	2.9	2
25	Novel Indices of Coronary Physiology. Circulation: Cardiovascular Interventions, 2020, 13, e008487.	1.4	44
26	Bleeding Risk Scores and Scales of Frailty for the Prediction of Haemorrhagic Events in Older Adults with Acute Coronary Syndrome: Insights from the FRASER study. Cardiovascular Drugs and Therapy, 2019, 33, 523-532.	1.3	11
27	Prognostic Value of QFR Measured Immediately After Successful Stent Implantation. JACC: Cardiovascular Interventions, 2019, 12, 2079-2088.	1.1	103
28	Impact of angiographic coronary artery disease complexity on ischemic and bleeding risks and on the comparative effectiveness of zotarolimus-eluting vs. bare-metal stents in uncertain drug-eluting stent candidates. International Journal of Cardiology, 2019, 277, 60-65.	0.8	2
29	Quantitative Flow Ratio Identifies Nonculprit Coronary Lesions Requiring Revascularization in Patients With ST-Segment–Elevation Myocardial Infarction and Multivessel Disease. Circulation: Cardiovascular Interventions, 2018, 11, e006023.	1.4	80
30	Determinants of radiation dose during right transradial access: Insights from the RAD-MATRIX study. American Heart Journal, 2018, 196, 113-118.	1.2	7
31	Evolving Routine Standards in InvasiveÂHemodynamic Assessment of Coronary Stenosis. JACC: Cardiovascular Interventions, 2018, 11, 1482-1491.	1.1	85
32	Diagnostic Performance of Inâ€Procedure Angiographyâ€Derived Quantitative Flow Reserve Compared to Pressureâ€Derived Fractional Flow Reserve: The FAVOR II Europeâ€Japan Study. Journal of the American Heart Association, 2018, 7, .	1.6	240
33	Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet, The, 2018, 392, 835-848.	6.3	215
34	Low FFR equal to low ischemia: Really?. International Journal of Cardiology, 2018, 265, 81.	0.8	0
35	Comparison of Verapamil versus Heparin as Adjunctive Treatment for Transradial Coronary Procedures: The VERMUT Study. Cardiology, 2018, 140, 74-82.	0.6	6
36	One-Year Clinical Outcomes of Forty-Eight Millimeter Everolimus-Eluting Stent Implanted in Very Long Lesions: A Propensity-Matched Comparison (The FREIUS Study). Journal of Invasive Cardiology, 2018, 30, 133-137.	0.4	2

#	Article	IF	CITATIONS
37	Radiation Exposure and Vascular AccessÂinÂAcute Coronary Syndromes. Journal of the American College of Cardiology, 2017, 69, 2530-2537.	1.2	61
38	Safety and Feasibility of Transradial Mini-Invasive Balloon Aortic Valvuloplasty. JACC: Cardiovascular Interventions, 2017, 10, 1375-1377.	1,1	18
39	Prospective Identification of Stent Fracture by Enhanced Stent Visualization System During Percutaneous Coronary Intervention. Circulation Journal, 2017, 81, 82-89.	0.7	7
40	A counseling program on nuisance bleeding improves quality of life in patients on dual antiplatelet therapy: A randomized controlled trial. PLoS ONE, 2017, 12, e0182124.	1.1	12
41	lschaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial. EuroIntervention, 2017, 13, 78-86.	1.4	21
42	Fractional flow reserve implementation in daily clinical practice: A European survey. International Journal of Cardiology, 2016, 207, 206-207.	0.8	14
43	Diagnostic Accuracy of Fast Computational Approaches to DeriveÂFractional Flow Reserve FromÂDiagnostic Coronary Angiography. JACC: Cardiovascular Interventions, 2016, 9, 2024-2035.	1.1	394
44	Fractional Flow Reserve Evaluation and Chronic Kidney Disease: Analysis From a Multicenter <scp>I</scp> talian Registry (the <scp>FREAK</scp> Study). Catheterization and Cardiovascular Interventions, 2016, 88, 555-562.	0.7	40
45	Bioresorbable vascular scaffold overlap evaluation with optical coherence tomography after implantation with or without enhanced stent visualization system (WOLFIE study): a two-centre prospective comparison. International Journal of Cardiovascular Imaging, 2016, 32, 211-223.	0.7	15
46	Occurrence, causes, and outcome after switching from ticagrelor to clopidogrel in a real-life scenario: data from a prospective registry. Platelets, 2016, 27, 484-487.	1,1	32
47	Is Bare-Metal Stent Implantation StillÂJustifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?. JACC: Cardiovascular Interventions, 2016, 9, 426-436.	1.1	135
48	A tool for predicting the outcome of reperfusion in ST-elevation myocardial infarction using age, thrombotic burden and index of microcirculatory resistance (ATI score). EuroIntervention, 2016, 12, 1223-1230.	1.4	29
49	Incidence, prognostic impact, and optimal definition of contrastâ€induced acute kidney injury in consecutive patients with stable or unstable coronary artery disease undergoing percutaneous coronary intervention. insights from the allâ€comer <scp>PRODIGY</scp> trial. Catheterization and Cardiovascular Interventions 2015 86 F19-27	0.7	30
50	Zotarolimus-Eluting Versus Bare-Metal Stents in Uncertain Drug-Eluting Stent Candidates. Journal of the American College of Cardiology, 2015, 65, 805-815.	1.2	248
51	Enhanced stent visualization systems during PCI: A case series and review of literature. Journal of Cardiology Cases, 2015, 12, 1-5.	0.2	12
52	Platelet aggregation values in patients with cardiovascular risk factors are reduced by verbascoside treatment. A randomized study. Pharmacological Research, 2015, 97, 1-6.	3.1	30
53	Fractional flow reserve: Current applications and overview of the available data. World Journal of Clinical Cases, 2015, 3, 678.	0.3	6
54	On-treatment platelet reactivity in patients with chronic obstructive pulmonary disease undergoing percutaneous coronary intervention: TableÂ1. Thorax, 2014, 69, 80-81.	2.7	28

#	Article	IF	CITATIONS
55	Randomized comparison of operator radiation exposure comparing transradial and transfemoral approach for percutaneous coronary procedures: rationale and design of the minimizing adverse haemorrhagic events by TRansradial access site and systemic implementation of angioX – RAdiation Dose study (RAD-MATRIX). Cardiovascular Revascularization Medicine, 2014, 15, 209-213.	0.3	17
56	Short- Versus Long-Term Duration of Dual Antiplatelet Therapy in Patients Treated for In-Stent Restenosis. Journal of the American College of Cardiology, 2014, 63, 506-512.	1.2	58
57	Two-Year Outcomes After First- or Second-Generation Drug-Eluting or Bare-Metal Stent Implantation in All-Comer Patients Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 20-28.	1.1	124
58	Transradial Coronary Catheterization and Intervention Across the Whole Spectrum of Allen Test Results. Journal of the American College of Cardiology, 2014, 63, 1833-1841.	1.2	123
59	Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial. European Heart Journal, 2014, 35, 2524-2529.	1.0	49
60	Seven french radial artery access for PCI: A prospective single-center experience. International Journal of Cardiology, 2014, 176, 1074-1075.	0.8	14
61	Impact of a recent hospitalization on treatment and prognosis of ST-segment elevation myocardial infarction. International Journal of Cardiology, 2013, 167, 296-297.	0.8	10
62	Coagulation Factors and Recurrence of Ischemic and Bleeding Adverse Events in Patients with Acute Coronary Syndromes. Thrombosis Research, 2013, 132, 151-157.	0.8	22
63	Effects of preâ€hospital clopidogrel administration on early and late residual platelet reactivity in STâ€segment elevation myocardial infarction patients undergoing primary intervention. Journal of Thrombosis and Haemostasis, 2013, 11, 192-194.	1.9	19
64	Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: Rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in Uncertain DES Candidates study. American Heart Journal, 2013, 166, 831-838.	1.2	18
65	Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). European Heart Journal, 2013, 34, 909-919.	1.0	108
66	Thrombin generation assay. Blood Coagulation and Fibrinolysis, 2012, 23, 680-687.	0.5	22
67	Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting. Circulation, 2012, 125, 2015-2026.	1.6	640
68	Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet, The, 2012, 380, 1482-1490.	6.3	412
69	Prasugrel Versus Tirofiban Bolus With or Without Short Post-Bolus Infusion With or Without Concomitant Prasugrel Administration in Patients With Myocardial Infarction Undergoing Coronary Stenting. JACC: Cardiovascular Interventions, 2012, 5, 268-277.	1.1	162
70	Medical and interventional management of patients with severe thrombocytopenia undergoing percutaneous coronary intervention. Journal of Thrombosis and Haemostasis, 2012, 10, 153-156.	1.9	5
71	Prospective Evaluation of On-Clopidogrel Platelet Reactivity Over Time in Patients Treated With Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2011, 57, 2474-2483.	1.2	315
72	Genetic determinants of on-clopidogrel high platelet reactivity. Platelets, 2011, 22, 399-407.	1.1	48

#	Article	IF	CITATIONS
73	Poor response to clopidogrel: current and future options for its management. Journal of Thrombosis and Thrombolysis, 2010, 30, 319-331.	1.0	53
74	Randomized, doubleâ€blind comparison of effects of abiciximab bolus only vs. onâ€label regimen on exÂvivo inhibition of platelet aggregation in responders to clopidogrel undergoing coronary stenting. Journal of Thrombosis and Haemostasis, 2010, 8, 1903-1911.	1.9	14
75	Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. European Heart Journal, 2010, 31, 35-49.	1.0	103
76	Safety evaluation of tirofiban. Expert Opinion on Drug Safety, 2010, 9, 801-819.	1.0	6
77	Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention. American Heart Journal, 2010, 160, 804-811.	1.2	66
78	The 5-Year Clinical Outcomes After a Randomized Comparison of Sirolimus-Eluting Versus Bare-Metal Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2009, 54, 1900-1901.	1.2	38
79	Prognostic value of serial platelet reactivity measurements on long-term clinical outcome in patients with ST-elevation myocardial infarction undergoing primary PCI. Journal of Thrombosis and Haemostasis, 2008, 6, 1824-1826.	1.9	15
80	Abciximab: a reappraisal of its use in coronary care. Biologics: Targets and Therapy, 2008, 2, 29.	3.0	8
81	Poor Responsiveness to Clopidogrel: Drug-Specific or Class-Effect Mechanism?. Journal of the American College of Cardiology, 2007, 50, 1132-1137.	1.2	82